Valuation: Avacta Group Plc

Market Cap 321M 431M 377M 347M 609M 41.07B 619M 4.15B 1.63B 20.23B 1.62B 1.58B 69.55B P/E 2026 *
-9.8x
P/E 2027 * -10.1x
Enterprise Value 315M 423M 370M 341M 598M 40.35B 608M 4.08B 1.6B 19.88B 1.59B 1.55B 68.34B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.8%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Avacta Group Plc

Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 22/06/2026
Director/Board Member 60 03/02/2020
Director/Board Member 62 06/07/2026
Change 5-day change 1-year change 3-year change Capi.($)
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.87B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.75B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average -0.67%-0.28%+52.07%+213.72% 26.84B
Weighted average by Cap. -0.89%-1.45%+51.26%+177.14%

Financials

2026 *2027 *
Net sales - -
Net income -33.4M -44.83M -39.21M -36.17M -63.39M -4.28B -64.45M -432M -170M -2.11B -168M -165M -7.24B -32.74M -43.93M -38.43M -35.44M -62.12M -4.19B -63.16M -423M -166M -2.06B -165M -161M -7.1B
Net Debt -5.58M -7.49M -6.55M -6.04M -10.58M -714M -10.76M -72.16M -28.34M -352M -28.1M -27.49M -1.21B 21.72M 29.14M 25.49M 23.51M 41.21M 2.78B 41.9M 281M 110M 1.37B 109M 107M 4.71B
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-